ALLO
Price:
$2.41
Market Cap:
$503.96M
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addi...[Read more]
Industry
Biotechnology
IPO Date
2018-10-11
Stock Exchange
NASDAQ
Ticker
ALLO
According to Allogene Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 12.25. This represents a change of -2.00% compared to the average of 12.50 of the last 4 quarters.
The mean historical Current Ratio of Allogene Therapeutics, Inc. over the last ten years is 11.46. The current 12.25 Current Ratio has changed 10.60% with respect to the historical average. Over the past ten years (40 quarters), ALLO's Current Ratio was at its highest in in the June 2020 quarter at 22.24. The Current Ratio was at its lowest in in the December 2017 quarter at 0.
Average
11.46
Median
12.38
Minimum
0
Maximum
16.80
Discovering the peaks and valleys of Allogene Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = Infinity%
Maximum Annual Current Ratio = 16.80
Minimum Annual Increase = -45.57%
Minimum Annual Current Ratio = 0
Year | Current Ratio | Change |
---|---|---|
2023 | 12.38 | 27.65% |
2022 | 9.70 | -42.27% |
2021 | 16.80 | 87.53% |
2020 | 8.96 | -45.57% |
2019 | 16.46 | 3.63% |
2018 | 15.89 | Infinity% |
The current Current Ratio of Allogene Therapeutics, Inc. (ALLO) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
12.96
5-year avg
12.86
10-year avg
11.46
Allogene Therapeutics, Inc.’s Current Ratio is greater than G1 Therapeutics, Inc. (2.48), greater than Heron Therapeutics, Inc. (2.38), less than Annexon, Inc. (21.81), greater than Sangamo Therapeutics, Inc. (1.03), greater than Beam Therapeutics Inc. (5.81), greater than Sana Biotechnology, Inc. (5.20), greater than Caribou Biosciences, Inc. (8.75), greater than Editas Medicine, Inc. (3.85), less than Theseus Pharmaceuticals, Inc. (29.93), greater than aTyr Pharma, Inc. (6.07), less than Relay Therapeutics, Inc. (15.64), greater than Century Therapeutics, Inc. (10.62), greater than Blueprint Medicines Corporation (3.71), greater than Intellia Therapeutics, Inc. (7.21), less than Verve Therapeutics, Inc. (14.64), greater than Prime Medicine, Inc. (8.23), less than iTeos Therapeutics, Inc. (18.08), less than Icosavax, Inc. (18.06), greater than Mirati Therapeutics, Inc. (7.54), greater than VectivBio Holding AG (9.14),
Company | Current Ratio | Market cap |
---|---|---|
2.48 | $376.17M | |
2.38 | $273.00M | |
21.81 | $607.51M | |
1.03 | $150.54M | |
5.81 | $1.92B | |
5.20 | $1.12B | |
8.75 | $155.42M | |
3.85 | $296.09M | |
29.93 | $181.50M | |
6.07 | $131.12M | |
15.64 | $835.47M | |
10.62 | $123.69M | |
3.71 | $5.47B | |
7.21 | $2.00B | |
14.64 | $473.47M | |
8.23 | $426.11M | |
18.08 | $540.52M | |
18.06 | $769.04M | |
7.54 | $4.12B | |
9.14 | $1.06B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Allogene Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Allogene Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Allogene Therapeutics, Inc.'s Current Ratio?
How is the Current Ratio calculated for Allogene Therapeutics, Inc. (ALLO)?
What is the highest Current Ratio for Allogene Therapeutics, Inc. (ALLO)?
What is the 3-year average Current Ratio for Allogene Therapeutics, Inc. (ALLO)?
What is the 5-year average Current Ratio for Allogene Therapeutics, Inc. (ALLO)?
How does the current Current Ratio for Allogene Therapeutics, Inc. (ALLO) compare to its historical average?